坦桑尼亚女孩接种一剂人乳头瘤病毒疫苗与两剂或三剂相比的免疫原性和安全性(DoRIS):一项开放标签、随机、非劣效性试验
在坦桑尼亚姆万扎9-14岁健康女学生中开展的开放标签、随机、3期非劣效性试验,930人随机接受2价或9价HPV疫苗1剂、2剂或3剂。24个月时,1剂组HPV 16 IgG血清阳性率99%,2剂和3剂组均为100%,达到预设非劣效标准;HPV 18血清阳性率未达非劣效标准,但所有组均超过98%。单剂可诱导稳健免疫应答。
要点
- 24个月时,1剂组99%参与者HPV 16 IgG血清阳性,2剂和3剂组均为100%,达到预设非劣效标准。
- HPV 18血清阳性率在1剂与2剂或3剂比较未达非劣效标准,但所有组均超过98%。
- 42名(4.5%)女孩发生53起严重不良事件,最常见为疟疾住院,1人死于疟疾,无严重不良事件被认为与接种相关。
核心结论
- 9-14岁女孩接种单剂2价或9价HPV疫苗可诱导长达24个月的稳健免疫应答,提示该减少剂次方案可能适用于目标年龄组女孩的HPV感染预防。
研究设计与样本
- 开放标签、随机、3期非劣效性试验,在坦桑尼亚姆万扎的政府学校招募9-14岁健康女学生。
- 2017年2月23日至2018年1月6日筛查1002名女孩,排除72名,纳入930名并随机分配至6组,每组155人,分别接受2价疫苗(Cervarix)或9价疫苗(Gardasil-9)的1剂、2剂或3剂。
- 主要结局为接种后24个月时1剂与同种疫苗2剂或3剂相比的HPV 16或HPV 18特异性血清阳性率,在符合方案人群中分析;安全性在总接种人群中分析。
- 试验注册于ClinicalTrials.gov,NCT02834637。
主要发现
- 922名参与者在规定窗口内完成所有计划剂次;930名参与者全部纳入总接种队列;24个月保留率为918/930(99%)。
- 符合方案队列中,24个月时接种1剂任一种HPV疫苗的参与者中99%为HPV 16 IgG抗体血清阳性,接种2剂者为100%,接种3剂者为100%,达到预设非劣效标准。
- 24个月时抗HPV 18血清阳性率在1剂与2剂或3剂比较未达非劣效标准,但所有组中超过98%的女孩有HPV 18抗体。
- 930名女孩中42名(4.5%)发生53起严重不良事件,最常见为因疟疾住院;1名女孩死于疟疾;组间事件数相似,无严重不良事件被认为与接种相关。
关键数值与推荐
- 主要结局非劣效性标准为预设标准,原文未报告具体阈值。
- HPV 16:1剂组血清阳性率99%,2剂组100%,3剂组100%,达到预设非劣效标准。
- HPV 18:1剂组与2剂或3剂比较未达非劣效标准,但所有组血清阳性率均超过98%。
临床怎么用
- 作者认为单剂2价或9价HPV疫苗诱导的免疫应答提示该减少剂次方案可能适用于目标年龄组女孩的HPV感染预防。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: An estimated 15% of girls aged 9-14 years worldwide have been vaccinated against human papillomavirus (HPV) with the recommended two-dose or three-dose schedules. A one-dose HPV vaccine schedule would be simpler and cheaper to deliver. We report immunogenicity and safety results of different doses of two different HPV vaccines in Tanzanian girls. METHODS: In this open-label, randomised, phase 3, non-inferiority trial, we enrolled healthy schoolgirls aged 9-14 years from Government schools in Mwanza, Tanzania. Eligible participants were randomly assigned to receive one, two, or three doses of either the 2-valent vaccine (Cervarix, GSK Biologicals, Rixensart) or the 9-valent vaccine (Gardasil-9, Sanofi Pasteur MSD, Lyon). The primary outcome was HPV 16 specific or HPV 18 specific seropositivity following one dose compared with two or three doses of the same HPV vaccine 24 months after vaccination. Safety was assessed as solicited adverse events up to 30 days after each dose and unsolicited adverse events up to 24 months after vaccination or to last study visit. The primary outcome was done in the per-protocol population, and safety was analysed in the total vaccinated population. This study was registered in ClinicalTrials.gov, NCT02834637. FINDINGS: Between Feb 23, 2017, and Jan 6, 2018, we screened 1002 girls for eligibility. 72 girls were excluded. 930 girls were enrolled and randomly assigned to receive one dose of Cervarix (155 participants), two doses of Cervarix (155 participants), three doses of Cervarix (155 participants), one dose of Gardasil-9 (155 participants), two doses of Gardasil-9 (155 participants), or three doses of Gardasil-9 (155 participants). 922 participants received all scheduled doses within the defined window (three withdrew, one was lost to follow-up, and one died before completion; two received their 6-month doses early, and one received the wrong valent vaccine in error; all 930 participants were included in the total vaccinated cohort). Retention at 24 months was 918 (99%) of 930 participants. In the according-to-protocol cohort, at 24 months, 99% of participants who received one dose of either HPV vaccine were seropositive for HPV 16 IgG antibodies, compared with 100% of participants who received two doses, and 100% of participants who received three doses. This met the prespecified non-inferiority criteria. Anti-HPV 18 seropositivity at 24 months did not meet non-inferiority criteria for one dose compared to two doses or three doses for either vaccine, although more than 98% of girls in all groups had HPV 18 antibodies. 53 serious adverse events (SAEs) were experienced by 42 (4·5%) of 930 girls, the most common of which was hospital admission for malaria. One girl died of malaria. Number of events was similar between groups and no SAEs were considered related to vaccination. INTERPRETATION: A single dose of the 2-valent or 9-valent HPV vaccine in girls aged 9-14 years induced robust immune responses up to 24 months, suggesting that this reduced dose regimen could be suitable for prevention of HPV infection among girls in the target age group for vaccination. FUNDING: UK Department for International Development/UK Medical Research Council/Wellcome Trust Joint Global Health Trials Scheme, The Bill & Melinda Gates Foundation, and the US National Cancer Institute. TRANSLATION: For the KiSwahili translation of the abstract see Supplementary Materials section.
引用
- Watson-Jones D, Changalucha J, Whitworth H, et al. Immunogenicity and safety of one-dose human papillomavirus vaccine compared with two or three doses in Tanzanian girls (DoRIS): an open-label, randomised, non-inferiority trial. Lancet Glob Health. 2022. PMID: 36113531. doi:10.1016/S2214-109X(22)00309-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。